Background: A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. The aim of this study was to replicate this finding in an independent Japanese cohort and to define a method to allow pretreatment prediction of anaemia in combination with other factors. Methods: Genotype 1b chronic hepatitis C patients (n=132) treated with pegylated interferon (PEG-IFN)-α and RBV for 48 weeks were genotyped for ITPA rs1127354 and examined for anaemia and treatment outcome. Results: Variants of the ITPA gene protected against severe anaemia throughout the 48-week treatment period and were associated with lower incidence of anaemia-related RBV dose reduction. A combination of the ITPA genotype with baseline haemoglobin (Hb) and creatinine clearance (CLcr) levels predicted severe anaemia with high accuracy (90% sensitivity and 62% specificity). Among a subset of patients with the IL28B genotype of TT at rs8099917, patients with variants of the ITPA gene were associated with a higher rate of receiving >80% of the expected RBV dose, a higher rate of sustained virological response (SVR), and a lower rate of relapse. Conclusions: The variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable TT genotype at rs8099917 of IL28B. A combination of ITPA genetic polymorphisms with baseline Hb and CLcr levels further improves the predictive accuracy of severe anaemia.
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Treatment with pegylated interferon (PEG-IFN) combined with ribavirin (RBV) is the most effective standard treatment for chronic HCV infection. Successful eradication of HCV is associated with a reduced risk of developing hepatocellular carcinoma. However, the rate of sustained virological response (SVR) is approximately 50% in patients with HCV genotype 1 [1, 2] . The probability of SVR decreases when the patients become intolerant to therapy and receive <80% of the planned dose of PEG-IFN and/or RBV [3] . One of the major reasons for intolerance to therapy is severe haemolytic anaemia induced by RBV [1] . The degree of haemolytic anaemia caused by RBV varies among individuals, and no reliable baseline predictors exist for this severe anaemia.
Recently, a genome-wide association study revealed that a single nucleotide polymorphism (SNP) at rs6051702 is strongly associated with RBV-induced haemolytic anaemia at week 4 of treatment [4] . This SNP was linked to two functional SNPs (rs1127354 and rs7270101) in the inosine triphosphatase (ITPA)
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Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin [5] [6] [7] [8] . Subsequent studies confirmed independently that variants of the ITPA gene are protective against haemolytic anaemia during the early weeks of treatment [9, 10] . Furthermore, Thompson et al. [9] showed that the variants are protective against anaemia over the entire 48-week course of therapy and are associated with reduced requirement for an anaemia-related dose reduction of RBV. Notably, despite these protective effects, variants in the ITPA gene were not associated with treatment outcome [4, 9] or showed only a marginal association [10] .
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In the present study, we aimed to replicate the association between ITPA genetic polymorphisms and RBVinduced anaemia in the early weeks, as well as throughout the entire course, of therapy in an independent Japanese cohort. In addition, for the general application of these genetic associations in clinical practice, we aimed to define a pretreatment prediction for severe anaemia in combination with other clinical covariates.
Methods

Patients
Data were collected retrospectively from a total of 132 genotype 1b chronic hepatitis C patients who were treated with PEG-IFN-α and RBV at Musashino Red Cross Hospital (Tokyo, Japan) and at Nagoya City University Graduate School of Medical Sciences (Nagoya, Japan). The inclusion criteria were: genotype 1b, HCV RNA titre >100 KIU/ml by quantitative PCR (Cobas Amplicor HCV Monitor version 2.0; Roche Diagnostic Systems, Indianapolis, IN, USA), no coinfection with HBV or HIV, no other causes of liver disease such as autoimmune hepatitis and primary biliary cirrhosis, and availability of DNA for the analysis of the genetic polymorphism of ITPA. Patients received PEG-IFNα2a (180 µg) and -α2b (1.5 µg/kg) subcutaneously every week and were administered a daily weight-adjusted dose of RBV (600 mg for patients weighing <60 kg, 800 mg for patients weighing 60-80 kg, and 1,000 mg for patients weighing >80 kg) for 48 weeks. Dose reduction of RBV was considered by physicians based on the clinical conditions of the individual patients or the recommendations on the package inserts: dose reduction from 800 mg and 1,000 mg to 600 mg or from 600 mg to 400 mg for haemoglobin levels <10 g/ dl and drug discontinuation when haemoglobin levels drop to <8.5 g/ dl. No patient received erythropoietin or other growth factors for the treatment of anaemia. PEG-IFN and RBV was stopped prematurely in 22 patients: in 15 patients due to non-virological response and in 7 patients due to adverse events. Written informed consent was obtained from each patient and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional ethics review committees.
Laboratory and histological tests
Blood samples were obtained before therapy and at 1, 2, 4, 6, 8, 12, 16, 20, 24, 36 and 48 weeks after the start of therapy, and were analysed for haematological tests, blood chemistry and HCV RNA. Genetic polymorphisms in an SNP located in exon 2 (rs1127354) and in intron 2 (rs7270101) of the ITPA gene were determined using ABI TaqMan Probes (Applied Biosystems, Carlsbad, CA, USA) [4] . Since a recent paper studying Japanese patients showed no variants in rs7270101 [10] and our preliminary genotyping data for 100 Japanese patients also showed no variations in rs7270101, rs1127354 was used for further analysis (major allele =C and minor allele =A). Genetic polymorphisms in the IL28B gene (rs8099917), an SNP recently identified to be associated with hepatitis C treatment response [11] [12] [13] [14] , was also determined by a DigiTag2 assay [15] . Viral factors affecting therapeutic efficacy was determined. A stretch of 40 amino acids in the NS5A region of HCV, designated as the interferon sensitivity-determining region (ISDR) [16, 17] and amino acid substitutions at positions 70 of the core region (Core70) [18] were determined by direct sequencing after amplification by reverse transcription and PCR as reported previously. Arginine at Core70 was defined as the wild type, and glutamine or histidine was defined as the mutant type. Baseline creatinine clearance (CLcr) levels were calculated using the formula of Cockcroft and Gault [19] : for males, CLcr= ([140 -age in years] × body weight in kg)/(72× serum creatinine in mg/dl) and for females, CLcr=0.85× ([140 -age in years]× body weight in kg)/ (72× serum creatinine in mg/dl). Fibrosis was evaluated on a scale of 0-4: F0 indicates no fibrosis, F1 indicates mild fibrosis, F2 indicates moderate fibrosis, F3 indicates severe fibrosis and F4 indicates cirrhosis according to the Metavir scoring system [20] . The end of treatment response was defined as an undetectable HCV RNA level by qualitative PCR with a lower detection limit of 50 IU/ml (Amplicor; Roche Diagnostic Systems) at the end of therapy. SVR was defined as an undetectable HCV RNA level 24 weeks after the completion of therapy. A relapse was defined as the reappearance of HCV RNA after the completion of therapy.
Statistical analysis
We analysed the association between an SNP of the ITPA gene (rs1127354) and the following: the incidence of haemoglobin (Hb) reduction of >3.0 g/dl at week 4 and the incidence of severe anaemia (Hb<10 g/ dl) at week 4 or at any time point during the therapy; the time-dependent decrease in Hb levels throughout the treatment period; the time-dependent requirement for RBV dose reduction throughout the treatment period; and the rate of virological response or relapse. Associations between pretreatment variables and anaemia were analysed by multivariable regression. The association between the ITPA polymorphisms and anaemia or treatment outcome was analysed by Fisher's exact test. The association between the ITPA polymorphisms and the time-dependent reduction in Hb levels or the requirement for RBV dose reduction was analysed by Kaplan-Meier survival analysis. SPSS software version 15.0 (SPSS Inc., Chicago, IL, USA) was used for these analyses.
Results
ITPA rs1127354 minor genotype alleles AA and CA were protective for anaemia during drug therapy
The baseline characteristics are listed in Table 1 . Genotyping of rs1127354 revealed that 4 patients were homozygous for the minor allele (AA), 95 were homozygous for the major allele (CC) and 33 were heterozygous (CA). The frequency of the minor allele A was 0.16. The ITPA genotype was not associated with any baseline factors including age, gender, Hb levels, CLcr, platelet counts, liver fibrosis, mutations in the ISDR and Core70 ( Table 2 ). The mean value of Hb reduction at week 4 was 2.2 g/dl and a reduction of >3.0 g/dl developed in 37 patients (28%) at week 4. Severe anaemia (Hb<10 g/dl) developed in 21 (16%) patients at week 4 of therapy and in 57 (43%) patients at any time point during the entire 48 weeks of therapy. Figure 1A and 1B shows the percentages of patients with anaemia according to the rs1127354 genotypes. At week 4, Hb reduction of >3.0 g/dl developed in 37 patients (39%) with the CC genotype, which is in contrast to 0 patients with the CA or AA genotypes ( Figure 1A ). Severe anaemia developed in 20 (21%) patients with the CC genotype, which is in contrast to only 1 (3%) patient with the CA genotype and 0 patients with the AA genotype (CC versus AA/CA, P=0.008; Figure 1B Table 1 . Clinical characteristics of the study population Continuous variables were described as mean (±sd) and categorical variables were described as frequency and percentage. a Severe anaemia defined as haemoglobin (Hb)<10 g/dl. Core70, amino acid substitutions at position 70 of the core region; ISDR, interferon sensitivity-determining region; ITPA, inosine triphosphatase gene. ITPA rs1127354 minor genotypes AA and CA were protective against the requirement for RBV dose reduction
The dose of RBV was reduced in 58 (43%) patients. Severe anaemia was the indication for dose reduction in 45 of the 58 (78%) patients. In the remaining 13 patients, the RBV dose was reduced because of other adverse events such as fatigue, skin eruption or loss of appetite. Figure 3 shows the time to the first RBV dose reduction during the 48 weeks of therapy. A dose reduction of RBV for any reason was less frequent and delayed in patients with the AA and CA genotypes compared to those with the CC genotype ( Figure 3A ; P=0.048).
The difference was more significant for anaemia-related RBV dose reduction ( Figure 3B ; P=0.004).
Other factors associated with severe anaemia during therapy
Since 18% of the patients with the protective ITPA genotype of CA developed severe anaemia, we analysed the patients for other predictive factors of severe anaemia. By univariable analysis, the rs1127354 CC genotype, female gender, older age, and lower baseline Hb levels, platelet counts and CLcr levels were associated with severe anaemia. Next, multivariable regression models with backward selection were used to identify the independent predictors of severe anaemia. Covariates included age, sex, fibrosis stage, baseline Hb levels, CLcr levels and platelet counts, and the rs1127354 genotype. The multivariable regression analysis showed that the rs1127354 CC genotype, a baseline Hb of <14 g/ dl and a baseline CLcr of ≤95 ml/min were independent predictors of severe anaemia at week 4 and at any time point during the 48 weeks of therapy (Table 3 ). Figure 4 shows the percentage of patients with Hb concentrations of <10 g/dl at any time point during therapy for the subgroups of patients stratified by rs1127354 genotype, baseline Hb levels and baseline CLcr levels. Among patients with the rs1127354 CC genotype, the risk of developing severe anaemia was more prominent in those with a baseline Hb<14 g/dl and a baseline CLcr≤95 ml/min (88%) compared to those with a baseline Hb≥14 g/dl and a baseline CLcr >95 ml/min (P<0.0001) or those with a baseline Hb<14 g/dl or a baseline CLcr≤95 ml/min (P=0.0036). Notably, the incidence of severe anaemia was only 12% in patients with the rs1127354 CC genotype if the baseline Hb was ≥14 g/dl and the CLcr was >95 ml/min. By contrast, there was a moderate risk of severe anaemia (33%) even in patients with the rs1127354 protective genotypes AA or CA when the baseline Hb was <14 g/dl and the baseline CLcr was ≤95 ml/min. Thus, patients who have >30% risk of severe anaemia had the following characteristics: rs1127354 CC genotype, baseline Hb<14 g/dl and CLcr≤95 ml/min; rs1127354 CC genotype and baseline Hb<14 g/dl or CLcr≤95 ml/min; and rs1127354 AA or CA genotype, baseline Hb<14 g/dl and CLcr≤95 ml/ min. The sensitivity and specificity of the combination of these three factors for the prediction of severe anaemia (Hb<10 g/dl) throughout the course of treatment was 89% (51/57) and 64% (48/75). Compared to the ITPA genotype alone, specificity improved from 41% to 64% with the same sensitivity (89%), indicating that the combination of the ITPA genotype, baseline Hb levels and baseline CLcr levels could improve the prediction accuracy. The AA/CA genotypes of rs1127354 were protective against the requirement for RBV dose reduction even after standardization by baseline Hb and CLcr ( Figure 3C ). The predictive model for anaemia and recommendations for monitoring and treatment were made for clinical practice application (Table 4) .
ITPA rs1127354 minor genotypes AA and CA were associated with higher adherence to RBV, higher rate of SVR and lower rate of relapse
The association of the rs1127354 genotype with the adherence to RBV or treatment outcome was analysed. When analysed in the entire population, the percentage of patients receiving >80% of the expected RBV dose, which was reported to be a threshold for an enhanced response to therapy [3] , was not significantly different among the rs1127354 genotypes. Treatment outcomes such as the end-of-treatment response, SVR and relapse were also not different among the rs1127354 genotypes (Table 5) . By contrast, SVR was closely associated with the IL28B genotype [11] [12] [13] [14] 21] : the rate of SVR was 0% (0/51) for IL28B minor type (TG/GG genotype at rs8099917) and 48% (39/81) for IL28B major type (TT genotype at rs8099917). This finding confirms that IL28B genotype is a significant factor for the prediction of SVR. Thus, we performed a subset analysis on subgroup of patients with the favourable IL28B genotype (TT at rs8099917). As a result, patients with the rs8099917 TT genotype and the rs1127354 AA or CA genotypes had a significantly higher rate of receiving >80% of the expected RBV dose (P=0.016), a higher rate of SVR (P=0.031), as well as a lower rate of relapse (P=0.046) compared to patients with the rs8099918 TT and rs1127354 CC genotype (Table 5) .
Discussion
In the present study, we confirmed that variants of the ITPA gene protect against severe haemolytic anaemia not only at the early stage of treatment, but also throughout the 48-week course of treatment in a Japanese cohort of genotype 1b chronic hepatitis C patients treated with PEG-IFN and RBV. We also replicated a previous study [9] that showed that the ITPA genotype is significantly associated with a time-dependent reduction of the RBV dose. Furthermore, we found that a combination of the ITPA genotype and the baseline Hb and CLcr levels improve the accuracy of predicting RBV-induced severe anaemia. Previous reports on the IDEAL [4] or ViraHep-C [9] studies did not find any association between the ITPA genotype and treatment outcome; however, we were able to demonstrate the association of the ITPA genotype with a higher adherence to RBV, a higher rate 
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Total patients, n% Hb<10 g/dl, n% 28 88% 54% 12% 15% 33% Patients with baseline Hb levels of <14 g/dl and CLcr levels of <95 ml/min had a higher incidence of severe anaemia among patients with the rs1127354 genotype CC (Hb<14 g/dl and CLcr≤95 ml/min versus Hb≥14 g/dl and CLcr>95 ml/min, P<0.0001; Hb<14 g/dl and CLcr≤95 ml/min versus Hb<14 g/dl or CLcr≤95 ml/min, P=0.0036). ITPA, inosine triphosphatase gene.
of SVR and a lower rate of relapse among a subset of Japanese patients with the favourable IL28B genotype (TT at rs8099917).
Haemolytic anaemia induced by RBV is one of the major adverse events of PEG-IFN and RBV therapy leading to dose reduction of RBV or premature termination of therapy [1] . RBV is essential for improving SVR by prevention of relapses and a breakthrough [22] , and a reduction of the RBV dose can lower the response rates considerably. It was reported that the maintenance of >80% of the expected RBV dose is associated with an increased SVR [23] . Thus, the prediction and prevention of RBV-induced haemolytic anaemia is clinically important. Previously, no reliable means were available to predict RBV-induced anaemia before therapy, but a recent genome-wide association study identified a strong association between two functional SNPs (rs1127354 and rs7270101) in the ITPA gene on chromosome 20 [4] and severe anaemia at week 4 of treatment. This genetic association has been replicated recently by two studies [9, 10] . However, the effect of these variants on the long-term development of anaemia or on the requirement for RBV dose reduction has been reported by only one study to date [9] . Therefore, validation of these results by an independent cohort with respect to different geographical areas, age, gender or race is needed. Although the clinical background of our cohort was different from that of the US cohort [9] , such as their race, older age (mean age of 57.5 years versus the median age of 48.5 years), and higher predominance of females (62% versus 35%), we were still able to replicate the results that the rs1127354 genotypes AA and CA are protective against anaemia throughout the 48-week course of treatment, especially within the 12 weeks following the initial treatment. We also replicated the association of this genotype with less requirement for RBV dose reduction. These results indicate that the ITPA genotype is universally an important determinant of RBVinduced haemolytic anaemia.
For the general application of these genetic associations in clinical practice, we aimed to further improve the accuracy of prediction by combining other clinical covariates. Among the patients with the rs1127354 CC genotype, the risk of developing severe anaemia was as high as 88% in those with baseline Hb levels of <14 g/dl and baseline CLcr levels of ≤95 ml/min, which is in contrast to only 12% in patients with Hb levels of ≥14 g/dl and CLcr levels of >95 ml/min. The rs1127354 AA and CA genotypes were protective against anaemia, but an exception occurred when patients (33%) with a baseline Hb level of <14 g/dl and a CLcr level of ≤95 ml/min developed severe anaemia. The combination of these three factors may therefore be useful in clinical practice, since it improved the specificity of prediction from 41% to 64% with the same sensitivity (89%) compared to examining just the ITPA genotype. These findings may have the potential to support individualized treatment strategies. Patients with the rs1127354 CC genotype, especially those with a baseline Hb level of <14 g/dl and a baseline CLcr level of ≤95 ml/min, require intensive monitoring for anaemia during therapy, and an early dose reduction of RBV or support by erythropoietin may be indicated for safety. By contrast, patients with the AA and CA genotypes, excluding those with a baseline Hb level of <14 g/dl and a baseline CLcr level of ≤95 ml/min, may be candidates for therapy with a higher RBV dose, which may lead to higher rates of SVR. The prediction of RBV-induced anaemia will remain an important issue even in the near future, since direct antiviral agents require RBV and PEG-IFN in combination in order to achieve higher SVR rates for genotype 1 [24, 25] and this combination will remain a standard therapy for other genotypes. In a previous study, there was no clear association between ITPase deficiency and treatment outcome [4, 9, 10] , even after a detailed subset analysis that excluded patients in whom RBV had been reduced for indications other than anaemia or after stratification by the IL28B genotype [9] . Thompson et al. [9] speculated that the lack of association may derive from several reasons such as an underpowered error due to the small number of patients, a high incidence of RBV dose reduction unrelated to anaemia, and the possibility that the ITPase deficiency may reduce antiviral efficacy. In the present study, we also failed to show associations between the ITPA genotype and treatment outcomes among the entire cohort. However, when patients were stratified by the IL28B genotype, which is now recognized as the major determinant of treatment outcome [11] [12] [13] [14] 21] , the AA and CA genotypes at rs1127354 were linked to a higher adherence to RBV, a lower rate of relapse and a significantly higher rate of SVR. One of the reasons for this discrepancy may be the lower incidence of anaemia-unrelated RBV dose reduction in our study compared to the participants of the Vira-Hep-C study (22% versus 48%) [9] . The effect of the ITPA genotype on RBV adherence and treatment outcome may be less apparent in patients who reduced their RBV dose in the absence of anaemia. Another possibility is that the difference in mean age may have some effect on this association between the ITPA genotype and treatment outcome since older age has been reported to compromise drug adherence or treatment outcomes [26, 27] . Our results indicated that, although IL28B genotype is the major determinant of SVR, the ITPA genotype may be used supplementary to predict the treatment outcome in patients with a favourable IL28B genotype (TT at rs8099917), as long as the RBV dose is not reduced in the absence of anaemia. Further studies involving larger populations in different geographical areas or races may be necessary to confirm this speculation.
In conclusion, variants of the ITPA gene, which could protect against haemolytic anaemia and RBV dose reduction, were associated with a high rate of SVR by standard PEG-IFN and RBV therapy in a subset of Japanese patients with the favourable IL28B genotype. A combination of the ITPA genetic polymorphism with baseline Hb and CLcr levels further improved the predictive accuracy of severe anaemia. These findings may have the potential to support selection of the optimum and personalized treatment strategy for individual patients.
